Every day, research uncovers new information about medical conditions and their treatment.

Volunteer involvement in clinical studies is a key part in the development and advancement of future therapies. Results collected from clinical studies have led to thousands of medications and devices becoming available to patients all over the world.

Will the CAREFNDR study cost anything?

During the study, you will be expected to complete regular visits to the research center. The study drug, study lab tests, study procedures, and safety assessments are provided at no cost. If you travel to the research center for your study visits, travel expenses may be reimbursed.

During the treatment period, you will be allowed to take certain rescue medications to manage your carcinoid syndrome symptoms when needed. Specific criteria will be established for this. The rescue medication will also be provided to you at no cost.

How can I learn more about the CAREFNDR study?

Thank you for your consideration. Taking part in clinical research like this study is an important part of developing potential new treatments for carcinoid syndrome. We look forward to hearing from you soon!

Learn more or find out if you might qualify to participate:

E-mail: clinicalstudies@crinetics.com

Are you living with **Carcinoid Syndrome** caused by Neuroendocrine Tumors?

Learn about a clinical study of an investigational oral medication.

What is a clinical study?

A clinical study (also known as a clinical trial) is designed to evaluate how safe and effective an investigational drug is in treating a specific disease or condition. The results of clinical studies help regulatory agencies decide if an investigational drug should be made available to patients.

Every clinical study is reviewed by an institutional review board or ethics committee, which helps ensure that the study is conducted safely and that the rights of study participants are protected. Clinical studies are conducted by experienced and trained medical professionals who monitor the health of participants during the study.

What is carcinoid syndrome?

Carcinoid syndrome is a group of symptoms that occur in some patients with neuroendocrine tumors (NETs). NETs are tumors that start in the cells in your neuroendocrine system, which makes and releases hormones in your body. In NETs, these cells begin to rapidly make more hormones than normal.

Carcinoid syndrome happens when the liver cannot filter out the hormones that are released by NETs. These excess hormones get into the bloodstream, often causing frequent diarrhea and spontaneous flushing, among other symptoms.

Taking part in a clinical trial is completely voluntary and you can choose to end your participation at any time and for any reason.

What is the purpose of the CAREFNDR study?

The CAREFNDR study is a phase 3 clinical study for adults living with carcinoid syndrome associated with NETs. The purpose of this study is to test how safe and effective an oral, once-a-day, investigational study drug called paltusotine is in people living with carcinoid syndrome associated with NETs. The study will look at whether paltusotine can reduce carcinoid syndrome symptoms (such as flushing and bowel movements) compared with placebo (a tablet that looks identical to the study drug but contains no active medication). Also, the study will evaluate if the study drug has any antitumor effect.

Paltusotine is an investigational study drug, which means it has not been approved by any regulatory authority and is still under investigation as a potential treatment for carcinoid syndrome. It can only be used in research studies like this one.

Who can participate in the CAREFNDR study?

You may be eligible to join the CAREFNDR study if you:

- Are at least 18 years old
- Have confirmed NETs and carcinoid syndrome
- Are currently treated with octreotide or lanreotide
  OR
  Are not currently treated with octreotide or lanreotide and experiencing symptoms

If you are currently taking octreotide or lanreotide for your carcinoid syndrome, you will need to be willing to stop taking these medications after you are enrolled in the study and under the supervision of the study doctor. A team of medical professionals will monitor your carcinoid syndrome, tumor status, and overall health throughout the study.

There are other eligibility criteria that you must meet to be able to participate in the study. Your study doctor will review your medical history and study criteria with you to see if you can be in the study, as well as discuss any potential benefit(s) and risk(s) associated with study participation.

What does the CAREFNDR study involve?

The study can last up to a total of 33 months, which is about 2 years and 9 months, and is divided into 4 main parts:

SCREENING PERIOD (up to 11 weeks)	Study procedures will be performed, and your medical records will be reviewed to see if you can participate. Study procedures may include blood samples, urine samples, pregnancy tests, and other medical assessments to evaluate your heart, eye condition, and tumor status. You will also be required to complete a daily diary to record your carcinoid symptoms. The screening period will require 2 visits to the research center.
BLINDED TREATMENT PERIOD (up to 16 weeks)	You will receive either the study drug or a placebo. Which one you receive is assigned randomly (like flipping a coin), and you will have 2 out of 3 chances of getting the study drug. “Blinded” means that neither you nor the study doctor will know to which treatment group you are assigned. The group of patients assigned to the study drug will be compared to those assigned to the placebo group to help researchers better understand the safety and effectiveness of the study drug. If you qualify and decide to participate, you will begin taking the study drug or placebo once a day for up to 16 weeks. You will return to the research center for 6 study visits during this period for study-related testing and procedures. You will also maintain study diaries to keep track of study dosing, carcinoid symptoms, and any potential health issues.
OPEN LABEL EXTENSION (OLE) PERIOD (up to 104 weeks)	At your study doctor’s discretion, at the end of the Blinded Treatment Period, you may be eligible to participate in a long-term, open-label extension (OLE) for up to 104 weeks where all patients will receive the study drug. If you decide to participate in the OLE portion of the study, you will continue to return to the research center for up to 11 study visits. Your tumor status and overall health will continue to be monitored during this period.
FOLLOW-UP PERIOD (up to 4 weeks)	After you stop taking the study drug, you will return to the research center to check on your health. A final study visit will occur four weeks after that.